Horizon Kinetics Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Horizon Kinetics Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$139K	Sell	22,648 -1,088	-5%	-$7.11K	﹤0.01%	308
2026 Q1	$164K	Sell	23,736 -1,088	-4%	-$8.39K	﹤0.01%	310
2025 Q4	$219K	Sell	24,824 -1,088	-4%	-$5.99K	﹤0.01%	287
2025 Q3	$129K	Buy	25,912 +1,088	+4%	+$5.04K	﹤0.01%	316
2025 Q2	$117K	Sell	24,824 -1,088	-4%	-$4.76K	﹤0.01%	331
2025 Q1	$119K	Hold	25,912	–	–	﹤0.01%	324
2024 Q4	$124K	Buy	25,912 +1,088	+4%	+$5.22K	﹤0.01%	327
2024 Q3	$116K	Sell	24,824 -1,088	-4%	-$5.83K	﹤0.01%	323
2024 Q2	$146K	Hold	25,912	–	–	﹤0.01%	297
2024 Q1	$106K	Hold	25,912	–	–	﹤0.01%	308
2023 Q4	$109K	Sell	25,912 -1,088	-4%	-$4.39K	﹤0.01%	307
2023 Q3	$117K	Hold	27,000	–	–	﹤0.01%	304
2023 Q2	$178K	Hold	27,000	–	–	﹤0.01%	297
2023 Q1	$183K	Buy	+27,000	New	+$190K	﹤0.01%	298

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Horizon Kinetics Asset Management's VNDA Position: Q2 2026 in Review

Horizon Kinetics Asset Management reduced its Vanda Pharmaceuticals (VNDA) stake by 4.6% in Q2 2026, selling an estimated $7.11K and leaving 22,648 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #308.

Horizon Kinetics Asset Management first reported a position in VNDA in Q1 2023 and has held it in 14 quarters since. The position peaked at $219K in Q4 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Horizon Kinetics Asset Management held 22,648 shares of Vanda Pharmaceuticals worth $139K as of Q2 2026.
Horizon Kinetics Asset Management sold 1,088 Vanda Pharmaceuticals shares in Q2 2026, an estimated $7.11K.
Vanda Pharmaceuticals made up ﹤0.01% of Horizon Kinetics Asset Management's portfolio in Q2 2026, its #308 holding.
Horizon Kinetics Asset Management first reported a position in Vanda Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
Horizon Kinetics Asset Management's Vanda Pharmaceuticals position peaked at $219K in Q4 2025.
172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.